US-based medical device company St Jude Medical has introduced its new Trifecta valve with glide technology (GT) in the US to treat patients afflicted with unhealthy, damaged or malfunctioning aortic heart valves.
The Trifecta GT tissue valve allows an enhanced valve delivery to the patient during implantation in challenging anatomies and while performing minimally invasive surgeries.
It is designed to resist wear and tear over time, offering an improved tissue-to-tissue contact when the leaflets open and close.
Additionally, the valve is treated with the St. Jude Medical Linx AC Treatment, which is an anti-calcification treatment intended to reducing tissue mineralisation (hardening).
The company noted that the valve’s fatigue-resistant titanium stent creates a supportive frame within a patient’s heart to promote durability.
Cardio-Thoracic and Vascular Surgical Associates cardio-thoracic surgeon Dr Trey Pluscht said: "The new tissue valve offers enhancements that will only make the implantation process smoother, providing a solution to patients with even the most challenging of cases.
"I welcome the opportunity to offer patients the life-changing benefits we have come to expect from this family of valves."
The Trifecta GT tissue valve addresses to patients afflicted with valve-related heart failure symptoms and foster a longer and a quality life for patients with damaged or diseased native heart valves.
The valve is considered as an enhanced version of the original Trifecta valve which offered patients a tissue valve that has exhibited functionality in a similar way as their native aortic valve.
It provides physicians a tissue valve option that is easier to implant while retaining its optimal hemodynamic performance.
The Trifecta GT tissue valve, which has secured the US Food and Drug Administration (FDA) approval last month, is CE Mark approved and is available in Europe.
Image: The Trifecta Valve with glide technology. Photo: courtesy of Business Wire.